These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25219760)

  • 1. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.
    Devillier R; Gelsi-Boyer V; Murati A; Prebet T; Rey J; Etienne A; D'Incan E; Charbonnier A; Blaise D; Mozziconacci MJ; Vey N
    Am J Hematol; 2015 Jan; 90(1):E22-4. PubMed ID: 25219760
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
    Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
    Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
    Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
    Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
    Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
    Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
    Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
    Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
    Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
    Fang H; He R; Chiu A; Viswanatha DS; Ketterling RP; Patnaik MS; Reichard KK
    Am J Clin Pathol; 2020 Apr; 153(5):656-663. PubMed ID: 31977035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SETBP1 mutation analysis in 944 patients with MDS and AML.
    Thol F; Suchanek KJ; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Kade S; Löffeld P; Banihosseini S; Bug G; Ottmann O; Hofmann WK; Krauter J; Kröger N; Ganser A; Heuser M
    Leukemia; 2013 Oct; 27(10):2072-5. PubMed ID: 23648668
    [No Abstract]   [Full Text] [Related]  

  • 11. Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia.
    Mannelli F; Ponziani V; Bonetti MI; Bencini S; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Rondelli T; Benelli M; Caporale R; Grazia Gelli AM; Peruzzi B; Longo G; Bosi A
    Exp Hematol; 2015 Oct; 43(10):869-879.e22. PubMed ID: 26101160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
    Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Molecular Sequencing Information as Related to 2008 and 2016 World Health Organization Classification of Acute Myeloid Leukemia and Myelodysplasia.
    Toth LN; de Abreu FB; Peterson JD; Loo EY
    Arch Pathol Lab Med; 2018 Sep; 142(9):1017. PubMed ID: 30141999
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients.
    Thol F; Kölking B; Hollink IH; Damm F; van den Heuvel-Eibrink MM; Michel Zwaan C; Bug G; Ottmann O; Wagner K; Morgan M; Hofmann WK; Göhring G; Schlegelberger B; Krauter J; Ganser A; Heuser M
    Leukemia; 2013 Mar; 27(3):750-4. PubMed ID: 22929522
    [No Abstract]   [Full Text] [Related]  

  • 15. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
    Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
    Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
    Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
    Yun S; Sharma R; Chan O; Vincelette ND; Sallman DA; Sweet K; Padron E; Komrokji R; Lancet JE; Abraham I; Moscinski LC; Cleveland JL; List AF; Zhang L
    Leuk Res; 2019 Sep; 84():106194. PubMed ID: 31357093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
    Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
    Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.